Wang et al.’s results show that trametinib also has the ability to induce ICD by sensitizing lung cancer cells to endoplasmic reticulum stress and triggering the release of DAMPs, and can be effective in treating KRAS-mutant LUAD when used in combination with interleukin-12 (IL-12) (179). This evidence concerns the gene KRAS and lung carcinoma.